Nanoscope Therapeutics Announces PMDA Acceptance and Priority Review of New Drug Application for MOGENRY® in Japan for the Treatment of Inherited Retinal Dystrophies

RegulatoryMOGENRY®Positive

AI Analysis

Summary

Nanoscope Therapeutics announced PMDA acceptance and Priority Review of MOGENRY® NDA in Japan for treating inherited retinal dystrophies, which could be the first disease-agnostic treatment for this indication. The drug has received Sakigake and Orphan Drug designations in Japan.

Outcome Details

PMDA accepted NDA with Priority Review status

Importance:7/10

Sentiment:

0.80

PMDAJapanOrphan DrugSakigake DesignationPriority ReviewInherited Retinal DystrophiesFirst-in-class potential

Related Companies

$TRAX

Read the original article

Published by PR Newswire Biotech on October 1, 2026 11:04 AM

Read Original